Veracyte Q3 Revenues Increase 75 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Monday that revenues in its third quarter improved 75 percent year over year.

The South San Francisco, Calif.-based company, which went public earlier this month, raising $58 million in net proceeds, reported revenues of $5.6 million for the three months ended Sept. 30, up from $3.2 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.